ENANTA PHARMACEUTICALS, INC. (EDP-305)

By June 19, 2019 Ongoing/In Follow Up

A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled

Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in

Subjects with Non-Alcoholic Steatohepatitis (NASH)

Leave a Reply